Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis
暂无分享,去创建一个
J. Sheridan | J. Elkins | V. Vexler | Ying Zhang | M. Tang | JeffreyR. Harris | K. Riester | L. Efros | Jia Shi